# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $13 price target.
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating prima...
HC Wainwright & Co. analyst Ed Arce maintains Genfit (NASDAQ:GNFT) with a Buy and raises the price target from $11 to $13.
GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S....
Iqirvo is a first-in-class oral, once-daily peroxisome proliferator-activated receptor (PPAR) agonist. Iqirvo was in-licensed f...
HC Wainwright & Co. analyst Ed Arce reiterates Genfit (NASDAQ:GNFT) with a Buy and maintains $11 price target.